Profile data is unavailable for this security.
About the company
Soligenix, Inc. is a late-stage biopharmaceutical company, which is focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The Company’s segments include Specialized Biotherapeutics, and Public Health Solutions. Its Specialized BioTherapeutics business segment is engaged in developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Its Public Health Solutions segment includes development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic-resistant and emerging infectious diseases and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2).
- Revenue in USD (TTM)0.00
- Net income in USD-11.46m
- Incorporated1987
- Employees14.00
- LocationSoligenix Inc29 Emmons Drive, Suite B-10PRINCETON 08540United StatesUSA
- Phone+1 (609) 538-8200
- Fax+1 (609) 452-6467
- Websitehttps://www.soligenix.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Imunon Inc | 0.00 | -14.33m | 10.01m | 25.00 | -- | 2.66 | -- | -- | -10.20 | -10.20 | 0.00 | 1.23 | 0.00 | -- | -- | 0.00 | -122.58 | -57.72 | -208.59 | -70.83 | -- | -- | -- | -7,752.42 | -- | -- | 0.00 | -- | -- | -- | 4.58 | -- | -38.98 | -- |
| BioVie Inc | 0.00 | -17.48m | 10.33m | 13.00 | -- | 0.5363 | -- | -- | -5.13 | -5.13 | 0.00 | 2.55 | 0.00 | -- | -- | 0.00 | -72.35 | -260.69 | -79.73 | -454.45 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 45.73 | -- | -- | -- |
| OSR Holdings Inc | 2.52m | -15.21m | 10.35m | -- | -- | 0.1161 | -- | 4.10 | -1.73 | -1.73 | 0.1939 | 3.46 | 0.0255 | -- | -- | -- | -22.03 | -- | -34.38 | -- | 18.35 | -- | -864.91 | -- | 0.2009 | -- | 0.0313 | -- | -- | -- | -697.08 | -- | -- | -- |
| Ainos Inc | 113.04k | -14.96m | 10.75m | 44.00 | -- | 0.7349 | -- | 95.13 | -4.29 | -4.29 | 0.0307 | 2.10 | 0.0042 | 0.12 | 3,768.00 | 2,569.09 | -55.34 | -38.46 | -60.63 | -55.22 | 82.62 | 35.93 | -13,231.35 | -1,122.70 | 2.67 | -19.92 | 0.5227 | -- | -83.02 | 12.06 | -7.93 | -- | 10.22 | -- |
| Phio Pharmaceuticals Corp | 0.00 | -7.95m | 10.87m | 5.00 | -- | 0.5938 | -- | -- | -2.73 | -2.73 | 0.00 | 1.70 | 0.00 | -- | -- | 0.00 | -91.57 | -73.65 | -107.58 | -86.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 33.96 | -- | -57.49 | -- |
| Chemomab Therapeutics Ltd - ADR | 0.00 | -10.09m | 11.04m | 16.00 | -- | 0.9827 | -- | -- | -5.87 | -5.87 | 0.00 | 1.82 | 0.00 | -- | -- | 0.00 | -60.63 | -- | -72.61 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.43 | -- | -- | -- |
| Soligenix Inc | 0.00 | -11.46m | 11.50m | 14.00 | -- | 1.48 | -- | -- | -3.66 | -3.66 | 0.00 | 0.7705 | 0.00 | -- | -- | 0.00 | -105.25 | -73.79 | -165.82 | -151.46 | -- | 22.19 | -- | -1,147.93 | -- | -- | 0.00 | -- | -85.78 | -51.89 | -34.62 | -- | -- | -- |
| Longeveron Inc | 1.44m | -21.34m | 11.91m | 25.00 | -- | 1.18 | -- | 8.29 | -1.34 | -1.34 | 0.0909 | 0.4732 | 0.0632 | -- | 6.65 | 57,480.00 | -93.88 | -70.26 | -114.04 | -83.92 | 74.88 | 44.57 | -1,485.11 | -683.81 | -- | -- | 0.00 | -- | 237.38 | -15.76 | -10.86 | -- | 51.32 | -- |
| Check Cap Ltd | 0.00 | -13.62m | 12.39m | 85.00 | -- | 2.64 | -- | -- | -2.33 | -2.33 | 0.00 | 0.6432 | 0.00 | -- | -- | -- | -114.23 | -61.64 | -130.02 | -67.99 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -43.15 | -- | -- | -- |
| GT Biopharma Inc | 0.00 | -34.45m | 12.52m | 1.00 | -- | 2.07 | -- | -- | -3.93 | -3.93 | 0.00 | 0.2266 | 0.00 | -- | -- | 0.00 | -459.62 | -172.68 | -1,377.41 | -460.87 | -- | -- | -- | -- | -- | -3,105.50 | 0.00 | -- | -- | -- | -161.73 | -- | -- | -- |
| Hookipa Pharma Inc | 9.35m | -73.31m | 12.82m | 82.00 | -- | 0.3684 | -- | 1.37 | -5.85 | -5.85 | 0.7457 | 2.82 | 0.0903 | -- | 1.74 | 114,036.60 | -70.79 | -40.82 | -91.08 | -50.56 | -- | -- | -784.01 | -266.20 | -- | -- | 0.00 | -- | 118.32 | 29.77 | 46.67 | -- | -37.28 | -- |
| Curanex Pharmaceuticals Inc | 0.00 | -1.30m | 12.97m | -- | -- | 0.9074 | -- | -- | -0.0497 | -0.0497 | 0.00 | 0.5043 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -142.76 | 0.00 | -- | -- | -- | -1,782.87 | -- | -- | -- |
| Kairos Pharma Ltd | 0.00 | -5.06m | 13.00m | 1.00 | -- | 1.70 | -- | -- | -0.3045 | -0.3045 | 0.00 | 0.3681 | 0.00 | -- | -- | 0.00 | -77.46 | -- | -92.07 | -- | -- | -- | -- | -- | -- | -94.05 | 0.00 | -- | -- | -- | -43.65 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| DRW Securities LLCas of 31 Dec 2025 | 124.80k | 1.24% |
| Geode Capital Management LLCas of 31 Dec 2025 | 80.40k | 0.80% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 53.91k | 0.54% |
| Jane Street Capital LLCas of 31 Dec 2025 | 37.90k | 0.38% |
| StoneX Group, Inc. (Investment Management)as of 31 Dec 2025 | 37.68k | 0.37% |
| UBS Securities LLCas of 31 Dec 2025 | 34.01k | 0.34% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 31.55k | 0.31% |
| XTX Markets LLCas of 31 Dec 2025 | 27.93k | 0.28% |
| Virtu Americas LLCas of 31 Dec 2025 | 15.12k | 0.15% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Dec 2025 | 3.59k | 0.04% |
